{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:36:33Z","timestamp":1793190993930,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T00:00:00Z","timestamp":1378166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.rmed.2013.06.001","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T17:15:32Z","timestamp":1372785332000},"page":"1538-1546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":197,"title":["Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25\u00a0mcg in\u00a0COPD"],"prefix":"10.1016","volume":"107","author":[{"given":"J.F.","family":"Donohue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Maleki-Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kilbride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kalberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2013.06.001_bib1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.001_bib2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, revised 2011. http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2011_Feb21.pdf [accessed 13.08.12]."},{"key":"10.1016\/j.rmed.2013.06.001_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1183\/09059180.00009902","article-title":"Reducing cholinergic constriction: the major reversible mechanism in COPD","volume":"15","author":"Brusasco","year":"2006","journal-title":"Eur Respri Rev"},{"key":"10.1016\/j.rmed.2013.06.001_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","article-title":"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmed.2013.06.001_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/15412555.2010.528812","article-title":"Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients","volume":"7","author":"van de Maele","year":"2010","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2013.06.001_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","article-title":"Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes","volume":"21","author":"van der Molen","year":"2012","journal-title":"Prim Care Respir J"},{"issue":"Suppl. 54","key":"10.1016\/j.rmed.2013.06.001_bib7","first-page":"5557","article-title":"Four weeks once daily treatment with tiotropium\u00a0+\u00a0olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients","volume":"36","author":"Maltais","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.001_bib8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/thx.2010.139113","article-title":"QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease","volume":"65","author":"van Noord","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2013.06.001_bib9","first-page":"A2259","volume":"185","author":"Reisner","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 55","key":"10.1016\/j.rmed.2013.06.001_bib10","first-page":"150s","volume":"38","author":"Reisner","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.001_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2013.06.001_bib12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.rmed.2012.03.012","article-title":"A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD","volume":"106","author":"Donohue","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2013.06.001_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1378\/chest.11-2231","article-title":"The efficacy and safety of the novel long-acting \u03b22 agonist vilanterol in COPD patients: a randomized placebo-controlled trial","volume":"142","author":"Hanania","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2013.06.001_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1378\/chest.09-0919","article-title":"Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study","volume":"137","author":"Hankinson","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2013.06.001_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.06.001_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2466-10-32","article-title":"MRC chronic dyspnea scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study","volume":"10","author":"Manali","year":"2010","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmed.2013.06.001_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.001_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2013.06.001_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jval.2012.06.018","article-title":"Development of the shortness of breath with daily activities questionnaire (SOBDA)","volume":"15","author":"Howard","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.rmed.2013.06.001_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's respiratory questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2013.06.001_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","article-title":"The MCID of the transition dyspnea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2013.06.001_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2013.06.001_bib23","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2013.06.001_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2013.06.001_bib25","unstructured":"Novartis. Indacaterol prescribing information. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/arcapta.pdf [accessed 15.08.12]."},{"key":"10.1016\/j.rmed.2013.06.001_bib26","unstructured":"GlaxoSmithKline. Salmeterol prescribing information. http:\/\/us.gsk.com\/products\/assets\/us_serevent_diskus.pdf [accessed 15.08.12]."},{"key":"10.1016\/j.rmed.2013.06.001_bib27","unstructured":"Boehringer-Ingelheim. Tiotropium prescribing information. http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Spiriva\/Spiriva.pdf [accessed 15.08.12]."},{"key":"10.1016\/j.rmed.2013.06.001_bib28","first-page":"A2938","article-title":"Safety and tolerability of the GSK573719\/vilanterol combination in patients with COPD","volume":"185","author":"Feldman","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.06.001_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.resp.2012.08.022","article-title":"Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients","volume":"185","author":"Decramer","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.rmed.2013.06.001_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1183\/09031936.00121411","article-title":"24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids","volume":"40","author":"L\u00f6tvall","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.001_bib31","unstructured":"GlaxoSmithKline. Salbutamol prescribing information. Available at: http:\/\/us.gsk.com\/products\/assets\/us_ventolin_hfa.pdf\/ [accessed February 2013]."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611113002138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611113002138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:28:59Z","timestamp":1760614139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611113002138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0954611113002138"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2013.06.001","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25\u00a0mcg in\u00a0COPD","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2013.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}